[en] Polymorphisms in the region of the interleukin-28B (IL28B) gene have recently been associated with spontaneous and treatment induced clearance of hepatitis C virus infection. The specific mechanisms of how IL28B polymorphisms affect HCV suppression remain unknown. It is a matter of ongoing debate how to incorporate the IL28B data into the current treatment algorithms with pegylated interferon-alpha and ribavirin. The eventual role of the IL28B genotype in new therapeutic regimes with direct antiviral agents needs to be explored in the ongoing and future clinical studies with these agents.
GE D., FELLAY J., THOMPSON A.J. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 2009, 461 (7262): 399-401.
SUPPIAH V., MOLDOVAN M., AHLENSTIEL G. et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet., 2009, 41 (10): 1100-4.
TANAKA Y., NISHIDA N., SUGIYAMA M. et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet., 2009, 41 (10): 1105-9.
RAUCH A., KUTALIK Z., DESCOMBES P. et al. Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study. Gastroenterology, 2010, 138 (4): 1338-45.
BALAGOPAL A., THOMAS D.L., THIO C.L. IL28B and the control of hepatitis C virus infection. Gastroenterology, 2010, 139 (6): 1865-76.
AFDHAL N.H., MCHUTCHISON J.G., ZEUZEM S. et al. Hepatitis C pharmacogenetics: State of the art in 2010. Hepatology, 2011, 53 (1): 336-45.
MCCARTHY J.J., LI J.H., THOMPSON A. et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology, 2010, 138 (7): 2307-14.
THOMAS D.L., THIO C.L., MARTIN M.P. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature, 2009, 461 (7265): 798-801.
TILLMANN H.L., THOMPSON A.J., PATEL K. et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology, 2010, 139 (5): 1586-92.
GREBELY J., PETOUMENOS K., HELLARD M. et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology, 2010, 52 (4): 1216-24.
GAD H.H., DELLGREN C., HAMMING O.J., VENDS S., PALUDAN S.R., HARTMANN R. Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J. Biol. Chem., 2009, 284 (31): 20869-75.
DELLGREN C., GAD H.H., HAMMING O.J., MELCHJORSEN J., HARTMANN R. Human interferon-lambda3 is a potent member of the type III interferon family. Genes. Immun., 2009, 10 (2): 125-31.
ROBEK M.D., BOYD B.S., CHISARI F.V. Lambda interferon inhibits hepatitis B and C virus replication. J. Virol., 2005, 79 (6): 3851-4.
LANGHANS B., KUPFER B., BRAUNSCHWEIGER I. et al. Interferonlambda serum levels in hepatitis C. J. Hepatol., 2010.
HONDA M., SAKAI A., YAMASHITA T. et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology, 2010, 139 (2): 499-509.
URBAN T.J., THOMPSON A.J., BRADRICK S.S. et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology, 2010, 52 (6): 1888-96.
LI J.H., LAO X.Q., TILLMANN H.L. et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology, 2010, 51 (6): 1904-11.
SCHERZER T.M., HOFER H., STAETTERMAYER A.F. et al. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. J. Hepatol., 2010.
MANGIA A., THOMPSON A.J., SANTORO R. et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology, 2010, 139 (3): 821-7.
MONTES-CANO M.A., GARCIA-LOZANO J.R., ABAD-MOLINA C. et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology, 2010, 52 (1): 33-7.
YU M.-L., HUANG C.-F., HUANG J.-F. et al. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology, 2011, 53 (1): 7-13.
MARTIN M.P., QI Y., GOEDERT J.J. et al. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J. Infect. Dis., 2010, 202 (11): 1749-53.
RALLON N.I., RESTREPO C., NAGGIE S. et al. Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. Aids, 2010, 25 (2): 269-71.
SALGADO M., KIRK G.D., COX A. et al. Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors. Aids, 2011, 25 (3): 385-7.
RALLON N.I., NAGGIE S., BENITO J.M. et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. Aids, 2010, 24 (8): F23-9.
MANGIA A., THOMPSON A., SANTORO R. et al. Rapid virological response vs IL28B CC genotype in HCV-1 infected patients treated with an individualized course of peginterferon and weight based ribavirin. Hepatology, 2010 (52): (S)A897.
DILL M.T., DUONG F.H., VOGT J.E. et al. Interferon-Induced Gene Expression Is a Stronger Predictor of Treatment Response Than IL28B Genotype in Patients With Hepatitis C. Gastroenterology, 2010, 140 (3): 1021-31.
DARLING J.M., AERSSENS J., FANNING G. et al. Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology, 2011, 53 (1): 14-22.
MONTES-CANO M.A., GARCÍA-LOZANO J.R., ABAD-MOLINA C. et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology, 2010, 52 (1): 33-7.
THOMPSON A.J., MUIR A.J., SULKOWSKI M.S. et al. Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus. Gastroenterology, 2010, 139 (1): 120-9.
STATTERMAYER A.F., STAUBER R., HOFER H. et al. Impact of IL28B Genotype on the Early and Sustained Virologic Response in Treatment-naive Patients With Chronic Hepatitis C. Clin. Gastroenterol. Hepatol., 2011: in press.
AKUTA N., SUZUKI F., HIRAKAWA M. et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology, 2010, 52 (2): 421-9.
FRIED M.W., BUTI M., DORE G.J. et al. Efficacy and safety of TMC435 in combination with peginterferon alfa-2a and ribavirin in treatment-naive genoorlent-: 1 HCV patients: 24-week interim results from the PILLAR study. Hepatology, 2010, 52 (Sup): LB-5.
MCHUTCHISON J., GOLDSTEIN D., SHIANNA K.V. et al. IL28B SNP geographical distribution and antiviral responses in a 28-day phase 2a trial of PSI-7977 daily dosing plus PEG-IFN/RBV. Hepatology, 2010, 52 (Sup): 815A.
LAGGING M., ROMERO AI., WESTIN J. et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology, 2006, 44 (6): 1617-25.
DILL M.T., DUONG F.H., VOGT J.E. et al. Interferon-Induced Gene Expression Is a Stronger Predictor of Treatment Response Than IL28B Genotype in Patients With Hepatitis C. Gastroenterology, 2010.
AKUTA N., SUZUKI F., KAWAMURA Y. et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J. Hepatol., 2007, 46 (3): 403-10.
FREEDMAN N.D., CURTO T.M., LINDSAY K., WRIGHT E.C., SINHA R., EVERHART J.E. Coffee is associated with virological response in chronic hepatitis C (CHC): findings from the hepatitis C long-term treatment against cirrhosis trial (HALT-C). Hepatology, 2010, 52 (Sup): 224A.
HARRISON S.A., ROSSARO L., HU K.Q. et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology, 2010, 52 (3): 864-74.
SULKOWSKI M., HARRISON S.A., ROSSARO L. et al. Impaired fasting glucose is associated with lower rates of sustained virologic response (SVR) in patients with genotype 1 chronic hepatitis C (CHC): retrospective analysis of the IDEAL study. Hepatology, 2010, 52 (Sup): 816A.
MOUCH S.A., ASSY N. Vitamin D supplementation improves viral response in chronic hepatitis C genotype 2/3 patients treated with peginterferon-alpha and ribavirin. Hepatology, 2010, 52 (Sup): 809A.